You appear to be avoiding my point on selective statistics, and you are trying to distract away by raising other issues. The fact is that SPL'S SP shot up in 2021 on the coattails of Covid, and fell back again just as quickly, as shown by the graph below.
View attachment 6341736
My point is that the SP in the biotech space is subject to large swings over short time frames, and is not a valid indicator of the true value of a company.
I suggest you read over the last quarterly report by the new, commercially orientated CEO, who replaced the retiring, science based old CEO. The next six months should expose the real commercial value of SPL.
manipulation at its best, page-56
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
